Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Completes Tender Offer for Iris

NEW YORK (GenomeWeb News) – Danaher today said that it has completed its $19.50-per-share offer to acquire Iris International.

The $338 million deal was signed by the firms in September. The purchase price represented a 45 percent premium to Iris' closing stock price of $13.42 on Sept. 14, the day before the agreement was announced.

The tender offer expired yesterday at 5:00 p.m. EDT. As of the expiration of the offer, 16,626,491 shares of Iris had been tendered and not withdrawn, representing nearly 92 percent of Iris's outstanding stock.

Chatsworth, Calif.-based Iris has three operating units: Iris Diagnostics, Iris Sample Processing, and Iris Molecular Diagnostics. The firm also operates a personalized medicine subsidiary developing assays based on the firm's Nucleic Acid Detection Immuno-Assay (NADiA) technology, which combines the specificity of monoclonal antibody capture with the sensitivity of real-time polymerase chain reaction detection. It also operates a CLIA lab and offers a test for identifying patients at risk of developing prostate cancer following a prostatectomy.

Iris will operate as a wholly owned subsidiary of Danaher.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.